POS3 BUDGET IMPACT ANALYSIS OF BISPHOSPHONATES FOR FRACTURES IN POSTMENOPAUSAL WOMEN
نویسندگان
چکیده
منابع مشابه
intravenous bisphosphonates for postmenopausal osteoporosis
abstract numerous clinical studies have shown bisphoshonates (bps) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. the use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. to improve upon the subo...
متن کاملUse of Oral Bisphosphonates in Primary Prevention of Fractures in Postmenopausal Women: A Population-Based Cohort Study
OBJECTIVE To compare incidence of first osteoporotic fracture in two cohorts of postmenopausal women, one treated with bisphosphonates and the other only with calcium and vitamin D. DESIGN Retrospective population cohort study with paired matching based on data from electronic health records. SETTING Women aged 60 years and older in 2005, from 21 primary care centers in a healthcare region ...
متن کاملCalcium for prevention of osteoporotic fractures in postmenopausal women.
A systematic review of the literature was conducted to assess the effectiveness of calcium supplements and/or dietary calcium for the prevention of osteoporotic fractures in postmenopausal women. Studies were identified by conducting a Medline search using the text words "fracture" and "calcium" for the period 1966 to March 1997 and by reviewing articles known to the authors. Only studies with ...
متن کاملDenosumab for prevention of fractures in postmenopausal women with osteoporosis.
BACKGROUND Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS We enrolled 7868 women between th...
متن کاملDenosumab for the prevention of osteoporotic fractures in postmenopausal women.
This paper presents a summary of the evidence review group (ERG) report into denosumab for the prevention of osteoporotic fractures in postmenopausal women. Denosumab has been shown in a large randomised trial to reduce the frequency of osteoporotic fractures when given subcutaneously at 6-monthly intervals. Compared with placebo, the relative risks of clinical vertebral and hip fractures were ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2006
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)64805-x